Choroidal vascularity index （CVI）, as a new biological parameter to quantitatively evaluate the state of choroidal vessels, has shown great potential in the diagnosis and treatment of ophthalmic diseases in recent years. CVI primarily calculated from images obtained via optical coherence tomography (OCT) and OCT angiography, demonstrates enhanced accuracy, stability, and clinical value with the advancement of three-dimensional imaging and artificial intelligence technologies. Compared with two-dimensional CVI, three-dimensional CVI comprehensively reflects the spatial distribution and structural changes of choroidal blood vessels by constructing three-dimensional choroidal models through ultra-widefield scanning. In various ophthalmic diseases, including age-related macular degeneration, central serous chorioretinopathy, diabetic retinopathy, and pathological myopia, CVI exhibits characteristic changes that not only contribute to understanding disease pathogenesis but also serve as indicators for early screening, individualized treatment, and efficacy monitoring. The application of artificial intelligence and deep learning technology improves the efficiency of automated CVI analysis, while integration with multimodal imaging further optimizes disease evaluation. Future efforts should focus on establishing standardized measurement protocols and quality control systems to promote its broader application and development in ophthalmology.
Mast cell (MC) play a crucial role in non-allergic fundus diseases, including uveitis, diabetic retinopathy, and age-related macular degeneration. MCs can profoundly influence the pathological processes of these diseases by regulating inflammatory responses, promoting angiogenesis, and facilitating tissue remodeling through the degranulation and release of mediators such as histamine, cytokines, and enzymes. The application of MC-associated inhibitors has been shown to effectively mitigate or inhibit the progression of these pathologies, offering a promising strategy for treating ocular diseases. Understanding the current state of MC research in fundus diseases will enhance our insight into their role in the pathophysiological mechanisms of these conditions and encourage further research aimed at providing more effective treatment options for patients.